Alerts will be sent to your verified email
Verify Email
ASTRAZEN
Positive for this company
Neutral for this company
Negative for this company
Insufficient data to analyse
AstraZeneca Pharma India is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. The company engages in execution of clinical studies to generate high quality data eligible for submissions to regulatory agencies across the world aimed at developing life altering medical products.
Astrazeneca Pharma I major competitors are Wockhardt, Pfizer, Eris Lifesciences, Natco Pharma, Alembic Pharma, Gland Pharma, Jubilant Pharmova.
Market Cap of Astrazeneca Pharma I is ₹22,257 Crs.
While the median market cap of its peers are ₹18,591 Crs.
Astrazeneca Pharma I seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annual Report | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | ||
| Earnings Release | Feb | Jun Aug Nov | Mar Jun Sep Dec | Jun | |||||||||||||||
| Investor Presentation | Mar Jun | Mar Jun Dec | Mar Jun Sep Dec | Jun Sep Dec | Dec | Mar | Dec | ||||||||||||
| Conference Call | |||||||||||||||||||
|
Conference Call SummaryCon Call Summary
Powered by Gemini
|
